Covovax and Corbevax vaccines, as well as the antiviral drug Molnupiravir, have been approved as an emergency treatment by the Central Drugs Standard Control Organization (CDSCO), a branch of the Ministry of Health and Family Welfare.
Related Post – How to read deleted WhatsApp messages on Android and recover them
Mansukh Mandaviya, the Minister of Health, made this announcement. He congratulated the nation through Twitter and said Molnupiravir was an antiviral drug that would be manufactured by 13 companies in the country for use in cases of emergency in treating COVID-19 in adult patients.
According to the minister, the CORBEVAX vaccine is the first RBD protein sub-unit vaccine to be developed in India. It was developed by the Hyderabad-based company Biologicals-E. India has now developed three vaccines. Pune-based Serum Institute of India will produce the nanoparticle vaccine, Kovovax. Earlier this year, the Serum Institute of India (SII) sought permission to market Kovovax for use in emergency situations. DCGI received SII’s application in October.
Omicron cases in 653
A significant amount of vaccines is being rolled out in the country to protect against Omicron variants of Covid infection. The focus of this episode is vaccination. Six hundred and fifty-three cases of Omicron have been reported in Indian states and union territories, of which 186 have been cured or have departed for other countries.
The Union Health Ministry released updated data on Tuesday. Maharashtra has the most cases of Omicron with 167 cases. 165 cases were reported in Delhi, 57 in Kerala, 55 in Telangana, 49 in Gujarat, and 46 in Rajasthan.
Vaccinations for people aged 15-18 will be available starting on January 1
A vaccine choice for children between 15 and 18 years old is ‘Covaccine’. Children can register for anti-Covid-19 vaccination through the ‘Covin’ portal beginning January 1. The information was given on Monday by officials. Anti-Covid-19 vaccines will be administered to children on January 3, according to the official. Children between the ages of 15 and 18 can register on the Covin website beginning on January 1st, said Dr. R.S. Sharma, the Cowin’s head. The Union Health Ministry released new guidelines on Monday that recommend Covaccine as the only vaccine option.
Those with serious diseases, such as heart disease, and frontline workers will receive the third dose of vaccine based on whether they received the second and third doses. In accordance with the guidelines that will go into effect on January 3, only people aged 15 and over will be allowed to register at Cowin. The vaccination will be available to those born in 2007 or earlier.
Related Post – How To Create A Google Knowledge Panel